Trial Profile
Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of Mantle Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 23 Feb 2024 Planned End Date changed from 1 Jan 2023 to 1 Dec 2024.
- 14 Jan 2022 An amendment was made which allowed accepting a response evaluation at 6 months instead of 12 months, by using CT scan and BM aspirate, to avoid excessive recruitment time as per results published in the Journal of Clinical Oncology
- 14 Jan 2022 Primary endpoint (Rate of complete remission) has been met as per results published in the Journal of Clinical Oncology